Skip to main content
Blood logoLink to Blood
. 2023 Nov 16;142(20):1758. doi: 10.1182/blood.2023022676

Jutzi JS, Marneth AE, Ciboddo M, et al. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022;140(11):1291-1304.

PMCID: PMC10667286  PMID: 37971758

Page 1295: In Figure 3B, the brackets on the right side of the graph were drawn incorrectly during the publication process. The upper bracket should end after the fourth entry in the color/symbol key, not after the third. The corrected Figure 3B is shown below.

Figure 3.

Figure 3.

In-depth validation of the N-glycan biosynthesis pathway as an essential pathway for growth of mutant CALR-expressing hematopoietic cells. (B) Growth curves of independent biological replicates and the 2 different sgRNAs were combined in the analysis. Cells were assayed either in the presence or absence of IL3 (+IL3/−IL3) for up to 96 hours. The assay was performed n = 3 for all 4 biological replicates of both genotypes. Statistical significance was determined by 2-way analysis of variance (ANOVA). Mean plus and minus standard error of the mean (SEM). ∗∗∗∗P < .00001. The most important statistical analysis is highlighted.


Articles from Blood are provided here courtesy of The American Society of Hematology

RESOURCES